Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 13/20 | 0.46 |
| ▸ | JAK3 | P52333 | 4/20 | 0.43 |
| ▸ | PLK4 | O00444 | 3/20 | 0.40 |
| ▸ | DAPK3 | O43293 | 3/20 | 0.40 |
| ▸ | DYRK3 | O43781 | 3/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.40 |
| ▸ | CDK1 | P06493 | 3/20 | 0.40 |
| ▸ | CDK2 | P24941 | 3/20 | 0.40 |
| ▸ | MARK3 | P27448 | 3/20 | 0.40 |
| ▸ | TYK2 | P29597 | 3/20 | 0.40 |
| ▸ | CLK2 | P49760 | 3/20 | 0.40 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.40 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.40 |
| ▸ | PKN2 | Q16513 | 3/20 | 0.40 |
| ▸ | MARK2 | Q7KZI7 | 3/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.40 |
| ▸ | PRKD2 | Q9BZL6 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11911421 | 0.86 | JAK2 (0.43) | JAK2JAK3PLK4DAPK3DYRK3 | |
| SCHEMBL13011677 | 0.83 | JAK2 (0.44) | JAK2JAK3PLK4DAPK3DYRK3 | |
| SCHEMBL1142337 | 0.83 | JAK2 (0.44) | JAK2JAK3PLK4DAPK3DYRK3 | |
| SCHEMBL1142340 | 0.83 | JAK2 (0.44) | JAK2JAK3PLK4DAPK3DYRK3 | |
| Hydrochloric Acid SCHEMBL1141267 | 0.82 | JAK2 (0.43) | JAK2JAK3PLK4DAPK3DYRK3 | |
| Hydrochloric Acid SCHEMBL1141269 | 0.82 | JAK2 (0.43) | JAK2JAK3PLK4DAPK3DYRK3 | |
| SCHEMBL1142228 | 0.81 | JAK2 (0.64) | JAK2JAK3PLK4DAPK3DYRK3 | |
| Hydrochloric Acid SCHEMBL1141989 | 0.80 | JAK2 (0.62) | JAK2JAK3PLK4DAPK3DYRK3 | |
| SCHEMBL13183156 | 0.80 | JAK2 (0.61) | JAK2DYRK3MAP4K4CDK1CDK2 | |
| SCHEMBL13183137 | 0.79 | JAK2 (0.44) | JAK2JAK3PLK4DAPK3DYRK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8232308-B2 | Methods for treating a disease in which Rho kinase is involved | UBE INDUSTRIES, LTD. (JP) | 2012-07-31 | — | — | US | disclosed |
| US-20110039891-A1 | Methods for treating a disease in which Rho kinase is involved | UBE INDUSTRIES, LTD. (JP) | 2011-02-17 | — | — | US | disclosed |
| US-7855222-B2 | Methods for treating a disease in which Rho kinase is involved | UBE INDUSTRIES, LTD. (JP) | 2010-12-21 | — | — | US | disclosed |
| US-20090264468-A1 | Methods for treating a disease in which Rho kinase is involved | UBE INDUSTRIES, LTD. (JP) | 2009-10-22 | — | — | US | disclosed |
| US-7563906-B2 | Indazole derivatives | UBE INDUSTRIES, LTD. (JP) | 2009-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264468-A1 | Methods for treating a disease in which Rho kinase is involved | RHOA, ROCK1, RHOT2 | JAK2 313/4885JAK3 750/4885PLK4 1713/4885 |
| US-20110039891-A1 | Methods for treating a disease in which Rho kinase is involved | RHOA, ROCK1, ROCK2 | JAK2 317/4885JAK3 684/4885PLK4 1692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.